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ABSTRACT 
Steven M. Van Scoyoc: Phase I Clinical Trial of a Chlorhexidine Diacetate 
Intraoral Delivery System in Medically Healthy Gingivitis Subjects. 
(under the direction of David W. Paquette DMD, MPH, DMSc; Lauren L. Patton DDS; 
Ray C. Williams DMD) 
Chlorhexidine diacetate (CDA) was incorporated into an ethylene vinyl acetate 
(EVA) mouthguard. This single center, 5-week, open-label trial, evaluated six medically 
healthy subjects with moderate gingivitis. Subjects wore the mouthguard 12 hrs/day for 21 
days. 
 Adverse events were recorded and the pharmacokinetic profiles of CDA in serum and 
saliva were evaluated.  Plaque samples were evaluated for changes in microbial susceptibility 
to CDA, bacterial counts characterized under aerobic and anaerobic conditions, and specific 
subgingival microorganisms. 
Results show limited adverse events, minimal systemic exposure to CDA, prolonged 
intraoral delivery, and no evidence of microbial CDA resistance. A reduction in the total 
bacterial counts of aerobic and anaerobic microbes, and an improvement in clinical signs of 
periodontal inflammation occurred. 
Data suggest that the CDA-EVA mouthguard is safe for human use with minimal 
systemic exposure. Additionally, CDA treatment does not alter the CDA-susceptibility of the 
oral flora and may reduce total bacterial counts. 
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Pharmacokinetic, Safety and Clinical Assessment 
of a Chlorhexidine Diacetate Intraoral Delivery System 
Abstract 
Our research team has incorporated 2.5% (by weight) chlorhexidine diacetate (CDA) into a 
novel intraoral delivery system. In vitro testing with the ethylene vinyl acetate (EVA) 
delivery system indicates sustained concentrations of chlorhexidine for up to 14 days. The 
proposed eventual use of this delivery system will include treatment of HIV-associated 
periodontitis patients. Objectives: 1) to evaluate the safety of a 2.5% CDA-loaded delivery 
system in medically healthy subjects with generalized moderate plaque-induced gingivitis, 
and 2) to document the pharmacokinetic profiles of CDA in serum following intraoral 
placement of the delivery system. Methods: This single center, 5-week, open-label trial, 
evaluated 6 medically healthy subjects with generalized moderate plaque-induced gingivitis. 
Subjects wore the EVA delivery system 12 hrs/day for 21 days in the maxillary arch. 
Examination of oral soft tissues and pharmacokinetic monitoring occurred at Baseline, Days 
1, 2, 3, 7, 14, 21 and 35. Blood chemistries, hematology and urinalysis were performed at 
screening and Day 21. All adverse events (AEs) were documented. Serum and saliva samples 
were analyzed using high performance liquid chromatography (HPLC). Periodontal probing, 
gingival index, plaque score, dental calculus and discoloration index assessments occurred at 
Baseline, Day 21 and Day 35. Results: All patients tolerated the delivery system, and 18 
non-severe adverse events were recorded. Calculus and discoloration indices were not 
increased with the use of the delivery system. No significant aberrations in blood chemistries, 
 2 
hematology or urinalysis occurred during the course of the study. Ninety-four percent of 
serum samples had levels of CDA below the detectable limit of 0.010 µg/ml, and all samples 
were ≤ 0.012µg/ml. Over the 21-day course of treatment, salivary CDA levels increased two 
hours post-dosing at all time points. Most strikingly, analysis of covariance revealed a 
significant decrease in mean pocket depth in the maxillary arch over 21 days (p<0.05) when 
controlling for changes in the mandibular arch. Conclusions: The data suggest that the drug 
delivery system is safe for human use with minimal systemic exposure, and CDA is released 
from the EVA polymer over 21 days of dosing. Trends in the data also suggest that local 
chlorhexidine diacetate may reduce the clinical signs of inflammation associated with 
periodontal disease. [Supported by DE15267-01, RR00046] 
Introduction 
Chlorhexidine (CHX) is a broad spectrum antimicrobial, which has activity against 
both Gram-negative and Gram-positive bacteria, yeast, fungi, and viruses.1-4 The oral rinse, 
chlorhexidine digluconate (0.2%) has been shown to be effective in reducing clinical signs of 
gingival inflammation5. However, CHX’s ability to maintain substantivity within saliva is 
reported to be limited to 5 hours following rinse use.6 Delivery of CHX at therapeutic 
concentrations at a constant rate over an extended period of time is desirable for the 
treatment of chronic periodontal conditions. Our group has developed a biocompatible 
copolymer (ethylene vinyl acetate or EVA) to release chlorhexidine diacetate (CDA) at a 
near constant rate over several weeks in vitro.7-9 The use of this CDA-containing polymer 
was submitted to the US Food and Drug Administration (FDA) as an Investigational New 
Drug (IND #73,126). 
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Individuals who are immunocompromised are at risk for oral opportunistic infections. 
These conditions can lead to significant morbidity for patients. In particular, patients with 
deficient immune responses are susceptible to destructive and necrotizing forms of 
periodontal diseases.10, 11 Our long term goal for the CDA-EVA mouthguard is the 
development of a sustained release intraoral delivery system for the treatment of human 
immunodeficiency virus (HIV)-associated oral infections. 
The aims of this phase I, single center, 35-day, open-label, clinical trial were: 1) to 
evaluate the safety of a 2.5% CDA-loaded delivery system in medically healthy subjects with 
generalized moderate plaque-induced gingivitis, and 2) to document the pharmacokinetic 
profiles of CDA in serum and saliva following intraoral placement of the delivery system. 
Materials and Methods 
Study Design 
Following protocol approval by the University of North Carolina Biomedical 
Institutional Review Board (IRB) at the University of North Carolina at Chapel Hill, six 
medically healthy adult subjects were recruited to participate. This population size was 
derived as a convenience sample based on logistical and not power considerations. 
For inclusion in this study, subjects had to be 18 years of age or older, have a 
functional complement of  ≥ 20 teeth with four teeth having probing depths of 4-5 mm and a 
minimum percent bleeding on probing score of at least 30%. Eligible subjects had to be able 
and willing to perform study procedures, and they had to provide written informed consent. 
Participants denied any periodontal or endodontic therapy other than prophylaxis within six 
months prior to enrollment. They also denied any history of a heart murmur, valvular disease, 
prosthetic joint replacement, chronic or active infectious disease and use of any medication 
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known to affect inflammation such as aspirin, nonsteroidal anti-inflammatory drugs, steroids, 
statins, phenytoin, calcium antagonists, cyclosporin and coumadin within one month of the 
screening exam. Subjects reported not using antibiotics or chlorhexidine mouthrinse within 
three months of screening. Subjects were excluded if they exhibited gross oral pathology, 
severe unrestored dental caries or clinically significant laboratory abnormalities. Subjects of 
both sexes were included; however, female subjects were excluded if they were pregnant, 
lactating or not using adequate contraceptive methods. 
The study design for this clinical trial included screening, treatment and post-
treatment phases (Figure 1). During the screening phase subjects received an intraoral 
examination. Within 14 days, subjects were recalled for laboratory testing including blood 
chemistries, complete blood counts, urinalysis, and urine pregnancy testing for females. 
Additionally, maxillary impressions were taken to fabricate the study mouthguards. 
Experimental Treatment 
Mouthguards containing 2.5% CDA in an EVA copolymer were custom fabricated 
for each subject for use over the 21-day treatment period. Accordingly, EVA sheets 
containing 2.5% CDA were vacuum-formed to fit the subject’s maxillary arch. Individual 
mouthguards were trimmed and smoothed to the dentition’s height of contour for a firm fit. 
Prior to dispensing the study mouthguard at visit 2, each mouthguard was weighed. 
Experimental mouthguards were dispensed in a dental appliance box labeled with the 
investigator’s name and address, patient ID number, IND statement and instructions for use 
and storage. These instructions included rinsing the mouthguard with water before placement 
and after removal, wearing the mouthguard 12 hours per day, avoiding prolonged washing of 
mouthguard, not wearing the mouthguard while eating, and leaving it out for 30 minutes after 
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brushing teeth. No mechanical intervention or oral hygiene instructions were given to 
subjects. Study mouthguards were stored at room temperature (20-25°C) at the test center or 
the subject’s home. 
Safety and Clinical Evaluation 
 On Day 0 (visit 2), subjects entered the testing facility for a one-night inpatient stay. 
Five milliliters of whole blood and 2ml of unstimulated whole saliva were collected within 
15 minutes prior to insertion of the delivery system. Blood draws and saliva collection 
occurred at 15 and 30 minutes post-dosing and at 1, 2, 3, 6, 9, 12, and 18 hours post-dosing. 
At hour 12, subjects removed the CDA-EVA delivery system. On Day 1 (visit 2 continued), 
blood and saliva samples were collected at 24 hours (following initial dosing on Day 0). The 
delivery system was reinserted and blood and saliva samples were collected two hours post-
dosing on Day 1. The delivery system was worn by the subjects for 12 hours per day for a 
total of 21 days. Subject compliance and adverse events (AEs) were assessed via the review 
of subject diaries. 
Subjects were evaluated clinically for safety and clinical outcomes on days 2, 3, 7, 14, 
and 21 of the treatment period. Safety assessments included measurement of vital signs and 
examination of the subjects’ extra- and intraoral tissues for signs of pathology. Assessment of 
tooth discoloration (DI)12 and calculus surface severity index (CSSI)13occurred at Baseline, 
Day 7 and Day 21. Any abnormal tissue findings were described with respect to onset, 
location, size (severity) and diagnosis. In addition, data were collected regarding adverse 
events. Clinical efficacy parameters included probing depth (PD), clinical attachment level 
(CAL), plaque index (PI),14 gingival index (GI),1515 and percent of sites bleeding to probing 
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(BOP) were recorded at screening and on Day 21 using a manual University of North 
Carolina (UNC-15) periodontal probe (Hu-Friedy Inc., Chicago, Illinois, USA). 
Two clinical examiners (HH and SV) were calibrated on all study parameters prior to 
study procedures. Reliability was confirmed with a greater than 90% intra-examiner 
agreement and greater than 85% inter-examiner agreement on clinical parameters (e.g., PD 
agreement within 1mm). One of the two examiners performed all clinical assessments for 
each subject throughout the treatment period  
Following the Day 21 visit, subjects entered a post-treatment period lasting two-
weeks. On Day 21, subjects discontinued use of the mouthguard and returned it to the 
examiners. Subjects were recalled on Day 35 for a final study visit (post-treatment visit) for 
safety assessments including an oral examination, saliva and serum collection and laboratory 
re-testing. 
Pharmacokinetic Evaluations 
Five milliliters (± 2ml) of whole blood were collected for each pharmacokinetic 
sample. Blood samples were allowed to coagulate for 30 minutes and then centrifuged at 
4,400 RPM for 20 minutes and stored immediately stored at -20°C until analysis. Whole, 
unstimulated saliva was collected via expectoration until approximately 2ml was obtained. 
Saliva samples were frozen -20°C until analysis. CDA drug concentrations in blood serum 
and saliva were measured using a novel developed and validated high performance liquid 
chromatography (HPLC)/Ultraviolet (UV) method. Briefly, extraction of the analyte from a 
serum and saliva matrix was performed by liquid-liquid extraction using tert-butyl methyl 
ether (MTBE). Accurately, 200ml of standards, quality controls (QCs), blanks, and 
unknowns were placed into a 2.0ml conical (eppendorf) tube. Next, 50µl of a 2µg/ml of the 
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internal standard (IS) phenacetin (PHN), and 50ml of 1.5M sodium hydroxide were added. 
Then 1.5ml of organic extraction solution MTBE was added to the tube. All tubes were 
vortex-mixed for 25 minutes followed by centrifugation for 3 minutes at 12,000 RPM. The 
extract was quickly frozen in an acetone dry ice bath. This acetone dry ice bath was prepared 
to hold 24 samples. The supernatant was poured into a clean 1.5ml conical tube and 
evaporated to dryness in a water bath (45°C) under a low stream of N2 gas for approximately 
15 minutes
. 
Dried samples were reconstituted in 50µl of mobile phase (1:1 mixture of 25 M 
sodium phosphate pH6.0: mobile phase B). The reconstituted solution tubes were vortex-
mixed for one minute and centrifuged at approximately 12,000 RPM for 5 minutes. 
Afterwards, the samples were transferred into HPLC 2-ml vials inside a polypropylene insert 
and placed in the instrument autosampler. Forty µl of the sample were injected. Sample 
analysis was conducted by reverse phase chromatography. The analyte and IS were eluted by 
a gradient mode of mobile phase from a RESTEK Ultra Aqueous C-18 (3.2 X 100 mm, 
3.0µm particle size) analytical column and RESTEK Ultra Aquous C18 (2.1 X 10mm, 
3.0µm) guard column. The two mobile phases were: Mobile Phase A (25mM sodium 
phosphate pH 3.0) and Mobile Phase B (500ml acetonitrile, 500ml methanol, 500µl 
heptafluorobutyric acid and 250µl triethylamine). The analyte peak was detected by an 
Agilent UV detector at 259nm. Concentration data in µg/ml were collected using Agilent 
Chemstation software. 
Statistical Analysis 
Baseline and demographic data were summarized with descriptive statistics (mean, median, 
standard deviation, range) for continuous data and with frequency tables for discrete data. 
Changes in clinical indices and periodontal probing parameters (from screening to Day 21) 
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were summarized with descriptive statistics. T-tests and an analysis of co-variance 
(ANCOVA). Adverse event data was summarized by frequency, severity and possible 
relationship to the study medication. Adverse events and other safety parameters were 
presented using the “intent-to-treat principle.” The concentration of CDA in serum and saliva 
for each time point was expressed as the mean, standard deviation and range. Standard 
pharmacokinetic parameters were estimated for saliva analyses. These parameters included 
area under the curve (AUC), maximum concentration (Cmax) and time to maximum 
concentration (Tmax), which was summarized with descriptive statistics. 
Results 
Study Subjects 
Of the seven subjects screened, all met the inclusion criteria, and six subjects were 
enrolled. All six subjects completed the study and were included in safety, clinical and 
pharmacokinetic analyses. The subjects had a mean age of 41±14 years (range, 27-58). Five 
(83.3%) were female, five (83.3%) were Caucasian, and one (16.6%) was African American. 
All subjects were non-smokers. The mean number of teeth per subject was 27.2 ±1. 
Safety results 
Safety tests performed at screening and Day 21 yielded blood chemistry (12 tests), 
hematology (10 tests) and urinalysis (17 tests). Out of the 468 tests, four were outside the 
normal range. One subject had a low post-treatment urine specific gravity (1.000, normal 
range: 1.003-1.030), one subject had high red blood cell distribution width (RDW) both pre- 
and post-treatment (16.8% and 16.5%, respectively; normal range: 12.0-15.0%), and one 
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subject had a high pre-treatment chloride level (110mEq/l, normal range: 98-107). All 
laboratory test aberrations were determined to be not clinically significant. 
All patients tolerated the CDA delivery system, and no severe AEs were reported. 
However, 18 non-severe AEs were reported over the course of the trial. All AEs were 
categorized as Grade I according to the CTCAE v3.0 scale.16 The most frequently reported 
AEs were oral lesions. There were nine lesions in three subjects. Six of the lesions were 
categorized as “unlikely related” or “not related” due to patients reporting a history of recent 
non-specific oral trauma. Three lesions were categorized as “likely related” to the study 
mouthguard, and all three ulcerations were reported in the same subject over a 1 month time 
period. No treatment was required for any of the oral lesions, and all lesions resolved upon 
completion of the study.  The second most reported AE was headache (7 reports in 3 
subjects). All AEs were graded as either “not related” or “unlikely related” to the study 
mouthguard The remaining two AEs were hematomas attributed to venipuncture, and no 
treatment was required. 
Initial CSSI and DI were low, and no significant changes in CSSI or DI occurred 
throughout the study (Table 1). Indeed, these indices decreased on average from Baseline to 
Day 21. 
All enrolled subjects completed the study and reported compliance with wearing the 
mouthguard for 12 hours/day throughout the duration of the study. 
Clinical indices 
At baseline, the mean pocket depth was 2.46±0.06mm, the mean CAL was 
2.19±0.22mm, the mean BOP was 48.45±10.49%, the mean GI was 1.00±0.42 and the mean 
PI was 0.45± 0.17 (Table 1). 
 10 
At visit 7 (Day 21), the mean pocket depth was 2.26±0.08mm, the mean CAL was 
1.98±0.23mm, the mean BOP was 30.76±9.22%, the mean GI was 0.54±0.18, and the mean 
PI was 0.38±0.17. Changes in PD, GI and %BOP (Baseline to Day 21) were statistically 
significant (p<0.05) (Table 2). Analysis of covariance revealed a significant decrease 
[Baseline: 2.38mm (SE=0.04), Day 21: 2.21mm (SE=0.04)] in mean pocket depth in the 
maxillary arch over 21 days (p<0.01) when controlling for changes in the mandibular arch 
(Table 3). Mean PI, CAL and BOP decreased while GI increased, although the changes were 
not statistically significant (Table 3). 
Pharmacokinetic Results 
The CDA concentrations in saliva over the first 24 hours for each subject are shown 
in Figure 2. The mean AUC for all patients (n=6) was 42.87µg·hr/ml ±42.68 (9.98-
128.15µg·hr/ml) (Figure 3). The concentration peaked (Cmax=5.69µg/ml±4.37, 1.70-
13.85µg/ml) at 2.54 hours±4.64 (0.25-12 hours) post mouthguard insertion. The 
concentration of CDA then decreased over 24 hours reaching 0.11±0.17µg/ml at 24 hours 
after the insertion of the mouthguard. All subjects showed a progressive decrease of CDA 
concentration following the removal of the mouthguard at 12 hours. Mean CDA levels both 
pre and post-dosing on days 1, 2, 3, 7, 14 and 21 are shown in Figure 4. At 2 hours post-
dosing, the mean concentration of CDA in the saliva increased at all timepoints. The change 
was statistically significant (p<0.05) on days 1, 3 and 21. Ninety-four percent (94%) of 
serum samples had CDA levels below the detectable limit of 0.010 µg/ml and all samples 
were ≤ 0.012µg/ml. 
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Discussion 
Immunocompromised patients are at risk for oral opportunistic infections. There is 
significant morbidity for patients with deficient immune responses who have destructive or 
necrotic forms of periodontal disease. Patients with HIV and deficient T helper (CD4+) 
lymphocytes are at risk for a destructive periodontal condition called “necrotizing ulcerative 
periodontitis” (NUP).11 The condition is marked by gingival papillary necrosis, gingival 
bleeding, fetid oral malodor, clinical attachment loss and alveolar bone resorption. Although 
a minority of HIV-infected patients present with NUP (approximately 5%), the condition is a 
source of morbidity (oral pain) for these individuals.17 In addition, the occurrence of NUP is 
predictive of a decrease in CD4+ lymphocyte counts below 200 in patients and an increased 
tendency to progress to  AIDS18, 19 Current treatment protocols for NUP include thorough 
debridement (scaling and root planing) of periodontal tissues and adjunctive systemic 
(peroral) antibiotics.20 Selective antibiotics such as metronidazole are most often used to 
limit the effects on the commensal flora of the gastrointestinal and other body systems; 
however, all peroral antibiotics pose a risk for overgrowth of opportunistic pathogens like 
Candida species. For these reasons, there is a great public health need to develop and test 
new, safe and efficacious interventions for NUP and other oral conditions in HIV-infected 
patients. The long term goal for our investigative group is the development of a sustained 
release intraoral delivery system for the treatment of HIV-associated oral infections. For this 
study, medically healthy gingivitis subjects were selected in order to evaluate the safety of 
the CDA-EVA intraoral delivery system. The use of healthy subjects or volunteers is 
standard practice for phase I trials on safety of novel drugs prior to evaluation in study 
 12 
subjects with systemic disease or more advanced oral disease who my experience a higher 
risk for toxicity and /or adverse events. 
The results of this study substantiate the claim for in vivo sustained long-term CDA 
release from the EVA mouthguard8 while demonstrating safety of this drug delivery system 
in medically healthy gingivitis subjects. The only reported AE in the oral environment was 
ulceration or tissue sloughing. It is unlikely that the CDA was responsible for ulcerations or 
desquamation as CHX gluconate mouthrinses have shown no effect on the keratinized oral 
epithelia following two years of daily or bi-daily rinses with 0.2% chlorhexidine gluconate.21 
In the present study, the three ulcerations that were attributed to the delivery system occurred 
in one subject. These ulcerations were likely a result of mechanical irritation from the 
mouthguard. The most commonly reported side effects associated with CHX digluconate oral 
rinses are: (1) an increase in staining of teeth and other oral surfaces, (2) an increase in 
calculus formation, and (3) an alteration in taste perception.22 Our results show no significant 
increase in calculus formation or discoloration with the use of the CDA-EVA system. 
Although taste perception was not measured directly, no self reports of taste alteration were 
noted. The lack of side effects from the CDA-EVA system indicates its potential to safely 
deliver chlorhexidine in vivo. 
As expected, no significant aberrations in blood chemistry or urinalysis occurred in this 
study. This result is consistent with a report of no altered white cell differential counts, liver 
function or kidney function in humans following two years daily rinsing with 0.2% 
chlorhexidine digluconate.23 
The pharmacokinetic results of this study show that subjects received a minimal systemic 
exposure to CDA as evidenced by mostly (94%) non-detectable serum levels throughout the 
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study. When detected, levels were below 0.012µg/ml. These results are consistent with a 
variety of studies demonstrating no detectable systemic exposure of subjects exposed to 
either an ingested CHX gluconate or a sustained-release 2.5mg CHX gluconate intrasulcular 
chip.24 It should be noted that although 6% of our samples did have detectable levels, our 
detection methods were 20 times more sensitive than the previously used methods.24 
Chlorhexidine has been shown to be poorly absorbed in human and animal tissues and is 
primarily metabolized in the liver and kidney.25 Soskolne et al.24 report no detectable levels 
of chlorhexidine in serum from 1 hour up to five days post-treatment with a sustained-release 
2.5mg chlorhexidine gluconate intrasulcular chip and another study 22shows the mean plasma 
level of chlorhexidine gluconate reached a peak of 0.206 µg/ml in humans 30 minutes after 
ingesting a 300 mg dose of the drug. Detectable levels of CHX gluconate were not present in 
the plasma of subjects ingesting CHX gluconate 12 hours after administration.22 Regarding 
systemic exposure, our results confirm that the 2.5% CDA-EVA delivery system is as safe as 
comparable low system exposures of chlorhexidine. 
The mean peak concentration of CDA in saliva for all subjects was 5.69µg/ml with a 
range of 1.70-13.85 µg/ml. The subjects in this study have a lower maximum salivary 
concentration of chlorhexdine than the reported concentration for subjects in other studies 
who rinsed with 0.2% CHX gluconate (Cmax= 153±27µg/ml).26 Lower levels of detectable 
chlorhexidine may indicate a limited ability for the 2.5% CDA-EVA delivery system to 
provide a dose capable of inhibiting the growth of oral pathogens at the current 
concentration. Stanley27 reports that the minimum inhibitory concentration (MIC) of many 
oral pathogens ranges from 31-250µg/ml. However, Arnold et al. report the MIC of P. 
gingivalis, S. mutans, and F. nucleatum to be less than 1µg/ml. 28 Additionally, chlorhexidine 
 14 
can alter microbial activity even at sub-MIC levels.29 Sub-MIC levels of chlorhexidine have 
been shown to alter adenosine triphosphate (ATP) synthase activity and membrane ion 
gradients in streptococci30 as well as inhibit the trypsin-like protease of P. gingivalis.31, 32 
Additionally, Marsh et al.33 showed that the inhibition of acid production by oral streptococci 
was due to chlorhexidine’s ability to inactivate the phosphoenolpyruvate-phosphotransferase 
sugar transport system. These effects of chlorhexidine at sub-MIC levels may significantly 
contribute to their effectiveness after the initial release of drug at higher concentrations. Most 
importantly, comparison of saliva concentrations when using the EVA mouthguard to rinsing 
with chlorhexidine digluconate may be inappropriate. Chlorhexidine rinses potentially 
deliver the drug throughout the entire mouth whereas the CDA-EVA mouthguard may target 
CDA delivery to the treated arch. There is a potential that the concentration of CDA is higher 
at the interface between the mouthguard and the maxillary tissue in the study while whole 
saliva collections may be significantly diluted. 
 An interesting observation regarding the concentration of CDA in saliva is that five of 
the six subjects (83.3%) demonstrated an increase in CDA concentration from 9 to 12 hours. 
All subjects entered the test facility in the late afternoon, and thus most subjects were 
sleeping between hours 9 and 12. Because salivary flow is decreased during sleep,34 it is 
possible that lower salivary flow contributed to a build up of CDA in the saliva and thus a 
higher concentration of CDA in the saliva at 12 hours. Further investigation into the increase 
of CDA concentrations after twelve hours should be evaluated in the phase II trial. 
It should be noted that salivary levels of CDA show great variability among subjects 
on days 1-21, both pre- and post-dosing. This may be attributed to variation in salivary flow 
and mouthguard surface area, which depends on a patients’ oral anatomy. Nonetheless, CDA 
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was released in measurable quantities from the delivery system in all subjects throughout the 
entire 21-day study. Even when CDA levels were below quantifiable limits pre-dosing, all 
subjects had detectable salivary levels of CDA two hours post-dosing at all time points. This 
difference was statistically significant on Day 1, 3 and 14. The small study sample size may 
account for the lack of significance at the other time points. These results substantiate in vitro 
studies demonstrating CDA release for several weeks from CDA-EVA films.288 
Trends toward improvement of clinical parameters used as surrogate measures of 
periodontal disease were observed with treatment. Most strikingly, a significant improvement 
in pocket depth was noted in the treated arch despite the small sample size of the study and 
despite the absences of any professional mechanical therapy. Although the results may be 
influenced by the Hawthorne effect or examiner bias since this was an open-label trial, the 
observed clinical improvement of periodontal parameters with CDA treatment in gingivitis 
subjects is encouraging. 
Conclusions 
The data suggest that the use of the CDA-EVA intraoral drug delivery system is safe 
for human use with minimal systemic exposure. Trends in the data suggest CDA released 
from an EVA delivery system may reduce the clinical signs of inflammatory periodontal 
disease. Interpretation of the results of this phase I clinical trial is limited due to the small 
sample size, lack of control group and open label design. A randomized, double blind, 
clinical trial in HIV subjects with periodontitis to confirm the safety and to elucidate the 
efficacy of this novel delivery system is underway. 
 
Microbial Assessment of Chlorhexidine Diacetate Mouthguard: 
Phase I Clinical Trial
Abstract 
Chlorhexidine diacetate (CDA) has been incorporated (2.5% by weight) into an 
ethylene vinyl acetate (EVA) intraoral delivery system for the proposed treatment indication 
of HIV-associated periodontitis. In vitro testing indicates sustained CDA delivery for at least 
14 days. Objectives: 1) to evaluate changes in the oral biofilm composition with CDA 
treatment in medically healthy subjects with gingivitis, and 2) to evaluate CDA-susceptibility 
patterns of plaque samples before, during and after CDA-EVA treatment. Methods: Six adult 
subjects with moderate plaque-induced gingivitis were recruited for this open-label, phase I 
trial. CDA-EVA mouthguards were fabricated to fit the maxillary arches of subjects and 
worn 12 hours/day for 21 days. Microbiological samples were obtained at Days 0 (pre-
dosing), 7 and 35, and quantitatively cultured using selective and differential media under 
appropriate atmospheres. In addition, the CDA-susceptibilities were determined by 
measuring the zones of growth inhibition (total and partial) of bacterial lawns that developed 
around standardized 2.5% CDA-EVA disks (6mm in diameter) placed on inoculated agar 
surfaces spread-plated with the individual subgingival plaque samples. Results: CDA-EVA 
treatment significantly decreased both aerobic (Day 0 vs. Day 7, p=0.05; Day 0 vs. Day 35, 
p=0.01) and anaerobic (Day 0 vs. Day 35, p=0.01) bacteria. In general, CDA-EVA treatment 
resulted in mean reductions of Porphyromonus gingivalis, Prevotella  intermedia and 
Candida species. All plaque samples were susceptible to total inhibition by CDA. No 
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significant changes were observed for mean zones of total or partial inhibition in the 
individual plaque samples before, during and after the treatment period. Conclusion: CDA-
EVA treatment does not alter the CDA-susceptibility profile of the oral flora and may reduce 
aerobic and anaerobic bacteria in healthy subjects with gingivitis. A phase II trial in HIV 
infected subjects may proceed. [Supported by DE15267-01, RR00046] 
Introduction 
One of the determining factors of periodontal health versus disease is the microbial 
composition found in the oral cavity. Accordingly the oral flora is very complex and the 
microbial population that forms in gingival sulci and on the surfaces of teeth of a patient with 
healthy gingiva differs from the bacterial populations found in moderate gingivitis and 
periodontitis.35 Microscopic examination of plaque from chronic periodontitis patients show 
a highly anaerobic (90%) and gram-negative (75%) flora.36 The diversity of microorganisms 
appears higher in the subgingival plaque of periodontitis patients than in health. Paster et al. 
estimated that there are approximately 415 species in subgingival plaque.37 Socransky et al. 
38
 analyzed subgingival plaque of 185 subjects with or without periodontitis and determined 
the presence and levels of 40 subgingival taxa. They showed that species cluster into five 
different complexes. Orange complex (Prevotella species, Fusobacterium species and 
Campylobacter species) and red complex (Porphyromonas gingivalis, Tannerella forsythia 
and Treponema denticola) species were found to have an association in that the bacteria from 
the red complex were rarely seen without the presence of bacteria from the orange complex. 
Additionally, the presence of red complex bacteria was strongly related to destructive 
periodontitis characterized by increased probing depth and bleeding on probing. Tanner  et 
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al. .39  studied the bacterial species associated with the initial development of a periodontal 
lesion. This longitudinal study attempted to identify the organisms associated with the shift 
from health to disease. Their data suggest that Tannerella forsythia, Campylobacter rectus 
and Selenomonas noxia were the major species that characterized sites converting from 
health to disease. Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans 
were detected infrequently in the study population, which suggests that these pathogens 
might arrive later during the disease process. This study demonstrates that bacteria that cause 
periodontal disease are not isolated organisms but are part of a developing bacterial biofilm. 
Individuals who are immunocompromised are at risk for oral opportunistic infections. 
In particular, patients with deficient immune responses are susceptible to destructive and 
necrotizing forms of periodontal diseases known as necrotizing ulcerative periodontitis 
(NUP).10, 11 Although the clinical presentation of HIV-associated oral conditions may differ 
from chronic periodontitis, the pathogenic bacteria associated with periodontal disease in 
HIV patients resembles that of normally healthy subjects suffering from periodontal 
disease.40 Microbiologic studies indicate high levels of P. intermedia and spirochetes are 
often seen in NUP patients.41 
Current non-surgical periodontal therapies targeted at reducing pathogenic bacteria 
include mechanical debridement and chemotherapeutics, as well as systemic and locally 
delivered antibiotics. The use of systemic antibiotics can lead to allergic reactions, digestive 
disturbances and overgrowth of opportunistic pathogens.  Thus, topical and locally delivered 
antimicrobials may provide benefits in the treatment of a variety of periodontal conditions 
while reducing risks for negative systemic side effects.   
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Our investigative group has incorporated chlorhexidine diacetate (CDA) into an 
ethylene vinyl acetate (EVA) copolymer for the treatment of periodontitis. The present study 
was conducted to evaluate changes in the oral biofilm with CDA-EVA treatment in 
medically healthy subjects with gingivitis and to evaluate susceptibility patterns of plaque 
samples before, during and after CDA-EVA treatment.  
Materials and Methods 
Study Design 
Subject recruitment and experimental treatment for this investigation are described 
elsewhere.42 Briefly, following a protocol approval by the Biomedical IRB of the University 
of North Carolina at Chapel Hill, six medically healthy consenting adult subjects were 
recruited to participate. This sample size was derived as a convenience sample and was 
chosen based on logistical and not power considerations. 
This was a single center, five-week, open label, phase I clinical trial. Subjects had 
moderate-plaque induced gingivitis defined as four or more teeth with 4-5mm pocket depths. 
Subjects were treated with a CDA-EVA mouthguard 12 hours per day for 21 days followed 
by a 14-day post-treatment period. Clinical indices were measured at Baseline (Day 0) and 
Day 21. Plaque samples were collected at Baseline, Day 7 and Day 35 (Figure 1). 
Plaque collection 
Four subgingival plaque samples were obtained from mesial surfaces of the maxillary 
first and second molars (four sites total) prior to mouthguard insertion at Baseline and on 
Days 7 and 35. For each designated site, the area was air dried and isolated with cotton rolls. 
Plaque samples were collected from the subgingival sites using medium-size sterile paper 
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points. Samples were placed into separate screw-cap tubes containing buffered mineral salts 
with sodium thioglycolate and L-cysteine (Liquid Dental Transport Medium, Anaerobe 
Systems, Morang Hill, CA, USA) (Figure 1). 
Culture technique and identification  
All samples were transported to the laboratory, maintained at room temperature and 
processed in less than two hours. Samples were transferred to 4ml of pre-reduced Wilkins 
Chalgren (WC) anaerobic broth (Oxoid.Ltd., Basingstoke, Hampshire, England) capped 
securely and vortexed. Ten-fold serial dilutions in WC broth were performed. 
All sample dilutions were spiral plated (Spiral Plater Model D from Microbiology 
International, Frederick, MD, USA) for quantitative culture using enriched non-selective, 
selective and differential media. Total recoverable colony forming units (CFU)/ml were 
determined for each sample. Total counts for aerobic growth were made on either chocolate 
agar in 5% CO2 at 37ºC or on sheep blood agar in ambient air at 37ºC, whichever yielded the 
higher count. Total counts for anaerobic growth were made on trypticase soy agar 
supplemented with sheep blood, heme, menadione and N-acetyl muramic acid (TSA-NAM 
from Anaerobe Systems, Morgan Hill, CA, USA) grown at 35ºC in a flexible film chamber 
(Coy Laboratories Inc., Ann Arbor, MI, USA) with an atmosphere of 10% H2-5% CO2-85% 
N2. 
In order to identify specific bacteria in the subjects’ dental plaque, the samples were 
grown on a variety of selective and non-selective media.  These media (Anaerobe Systems, 
Morgan Hill, CA, USA or from Difco Laboratories, Detroit, MI, USA) are listed in Table 4. 
Total counts and subcounts based on distinct colony types were determined on each of these 
media. These aerobic and anaerobic media along with biochemical and morphology analysis 
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permitted the quantitative identification of the following microorganisms: P. gingivalis, T. 
forsythia, Prevotella. intermedia, Capnocytophaga species, Peptostreptococcus anaerobius, 
P. micros, P. nigrescens, Fusobacterium nucleatum, Fusobacterium periodonticum, F. 
species, Eikenella corrodens, C. rectus, C. gracilis, Bacteroides fragilis, Actinomyces 
species, A. actinomycetemcomitans, Candida albicans, non-albicans Candida species, 
Enterococcus faecalis, Staphylococcus aureus, Streptococcus pyogenes, S. mutans, 
Lactobacillus acidophilus, Haemophilus species, S. pneumonia, all enteric bacteria, group B 
and group D Streptococci.  
Sensitivity Analysis 
Each of the four subgingival plaque samples from subjects on Days 0, 7 and 35 were 
analyzed for sensitivity to CDA. Aliquots of 1ml of undiluted samples in WC were spread 
plated manually on TSA-NAM plates. If 1ml was not available, a 1:10 dilution was used. 
Disks (6mm in diameter) cut from standard 2.5% CDA-EVA films were evenly spaced on 
the freshly inoculated agar surface. These plaque bacteria were allowed to grow to a 
confluent lawn in an atmosphere of 10%H2-5%CO2-85%N2 at 35ºC. Zones of total inhibition 
were measured as diameter using calipers and recorded in millimeters. Additionally, zones of 
partial inhibition, defined as clear demarcations where there was discernible inhibition of 
some, but not all of the mixture of bacteria, were recorded. 
Results 
Study subjects and treatment 
Six subjects, met the inclusion criteria, signed consent forms and were enrolled in the 
study. All subjects who entered the study completed the study and were included in the 
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microbial analyses. The subjects had a mean age of 41±14 years (range: 27-58), and the 
mean number of teeth per subject was 27.2 ±1. Five (83.3%) subjects were Caucasian, and 
one (16.6%) was African American. Five (83.3%) of the subjects were female, and all 
subjects were non-smokers. In general, study treatments were well-tolerated, and the safety 
and clinical effects are detailed elsewhere42 
Resistance evaluation 
Mean zones of total and partial inhibition are shown in Figure 5. The mean zone of 
total inhibition on Day 0 was 12.15±1.97mm. On Day 7 and 35, the mean zones of total 
inhibition were 12.23±1.69mm and 12.27±1.28mm, respectively. There were no statistically 
significant differences in the zones of inhibition between Days 0 and 7 (p=0.81) or between 
Days 0 and 35 (p=0.46). The partial zones of inhibition also showed no statistically 
significant changes from Day 0 to Day 7 (p=0.78) and Day 0 to Day 35 (p=0.66). 
Microbial Load 
Total recoverable CFUs/ml from plaque samples are shown in Figure 6. On Days 0, 
7, and 35 the total recoverable CFU for aerobic species was 4.92±0.22 (SE) log10 CFU/ml. 
On days 7 and 35 the levels were 4.57±0.14 (SE) log10 CFU/ml and 4.17±0.20 (SE) log10 
CFU/ml, respectively. Total recoverable anaerobic CFUs on days 0, 7 and 35 were 5.15±0.22 
(SE) log10 CFU/ml, 5.36±0.33 (SE) log10d CFU/ml, 4.72±0.25 (SE) log10 CFU/ml, 
respectively. Overall, there was a statistically significant decrease of both aerobic (Day 0 vs. 
Day 7, p=0.05; Day 0 vs. Day 35, p=0.01) and anaerobic (Day 0 vs. Day 35, p=0.01) bacteria 
with CDA treatment. 
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Plaque Composition 
 Specific bacteria identified in the four subgingival sites from the six subjects at 
Baseline (Day 0), Day 7 and Day 35 are summarized in Figure 7. Over the 35-day study, the 
percent of sites harboring P. gingivalis, P. intermedia, Capnocytophaga species, P. 
anaerobius and E. corrodens decreased. In contrast from Baseline to Day 35, there was an 
increase in the percentage of sites harboring P. nigrescens, F. nucleatum and C. gracilis.  
P. gingivalis was found in all subjects during at least one timepoint throughout the study. T. 
forsythus, P. micros, Wolinella species, and C. rectus were not recovered in any of the 
samples. Candida species were present at baseline in nine samples from three of the patients. 
The number of positive sites decreased to eight on Day 7, and to one site on Day 35 (Figure 
8). 
Discussion 
Chlorhexidine (CHX) is a commonly used active chemotherapeutic for managing 
periodontal diseases. Chlorhexidine is marketed worldwide as a 0.12% or 0.2% mouthrinse,5, 
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 but it is also available in a variety of other forms including gels,43 toothpastes,44 and a 
biodegradable local delivery chip45 that is placed subgingivally. In general, these 
formulations are based on the diacetate salt of CHX. 
CHX is a broad spectrum antimicrobial agent with activity against a wide range of 
Gram-positive and Gram-negative bacteria found in the supragingival and subgingival 
plaque.46, 47 Its mode of action varies but includes lysing cell membranes, disrupting 
structural organization and congealing of cytoplasm at high concentrations.48 Additionally, 
CHX has a dicationic charge, which allows it to bind to oral tissues, and which enhances 
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substantivity in the oral cavity. A clinical study in gingivitis patients showed that rinsing with 
a 0.12% CHX mouthrinse reduced the number of black pigmented Bacteroides species after 
6 months.49 Another treatment group from this same trial had subgingival irrigation with a 
0.06% CHX and demonstrated a significant reduction in the number of Gram-negative 
anaerobic rods and black-pigmented Bacteroides species.49 After 3 months, both CHX 
regimens resulted in an increase in Gram-positive facultative anaerobic species, which are 
often associated with periodontal health. 
Previous reports by both Daneshmand et al.50 and Grisi et al.51 failed to show that the 
adjunctive use of a subgingival chlorhexidine chip (PerioChip, DexcelPharma, Jerusalem, 
Israel) improved microbial levels of periodontal pathogens over scaling and root planing 
alone.  However, a recent multicenter randomized controlled clinical trial by Paolantonio and 
coworkers demonstrated that following the adjunctive use of a chlorhexidine chip in 
experimental sites with probing depths ≥ 5mm and bleeding on probing, total bacterial counts 
at 15 days and 1 month were significantly lower than in sites treated with scaling and root 
planing alone.52 Additionally, sites treated with the chlorhexidine chip had significantly 
greater decreases at 15 days and 3 months for C. rectus, and at 15 days, 1 month and 3 
months for T. forsythia over scaling and root planing alone. In the current phase I clinical 
trial, gingivitis subjects did not harbor C. rectus or T. forsythia either pre- or post-treatment. 
We did however observe a reduction in the number of sites culturing positive for other 
periodontal pathogens such as P. gingivalis and P. intermedia with CDA treatment. 
During this phase I clinical trial, it was important to determine if treatment would 
lead to the formation of bacterial resistance to chlorhexidine. Stickler and colleagues have 
reported the existence of CHX resistant strains of Pseudomona, Proteus and Providencia.53 
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Additionally, S. aureus has been shown to be resistant to CHX. S.aureus also has the ability 
to transfer resistance to E. coli via recombinant plasmids.54 According to one report, Serratia 
marcescans had increased resistance to CHX following repeated exposure to various contact 
lens solutions containing 0.001 to 0.006% chlorhexidine.55  Additionally, Pseudomonas 
aeruginosa showed a greater than seven-fold increase in its minimum inhibitory 
concentration (MIC) to CHX digluconate following six days of repeated exposure to 5mg/l of 
CHX.56 Another study by Brooks and coworkers demonstrated that some isolates of P. 
aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii could multiply in 1:2 
dilution of 2% chlorhexidine liquid soap.57 
In contrast, Russell and Day argue that laboratory tests are inconclusive as to whether 
organisms can be pressured to become highly resistant to CHX.58 Cookson et al.59 subjected 
methicillin-resistant Staphylococcus aureus (MRSA) and methecillin-sensitive 
Staphylococcus aureus (MSSA) to repeated exposures of chlorhexidine in vivo and in vitro, 
but failed to document resistance formation. In dental studies, investigators who monitored 
CHX oral continuous rinsing twice a day for 2 years in humans, reported no reduction of 
plaque inhibition and only minor reduction of salivary bacterial sensitivity.5, 23 Walker 
reviewed the microbiological effects of mouthrinses and concurs that resistance formation is 
not seen with extended use of CHX.60 
The present study supports the use of chlorhexidine as a safe topical 
chemotherapeutic for the treatment of periodontal disease. Throughout the study, CDA 
produced a consistent zone of total inhibition of bacterial growth when tested on the subjects’ 
plaque samples. In addition, there were differential sensitivities of the various bacterial 
populations in the plaque samples as evidenced by partial zones of inhibition. Baseline data 
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show that all plaque samples collected from all subjects were sensitive to CDA as 
demonstrated by zones of total and partial inhibition when exposed to CDA. Additionally, 
similar zones of total inhibition and partial inhibition were measured at all subsequent time 
point. These data indicate that over the 21-day treatment and the 14 day post-treatment 
periods, the oral flora did not develop or select for resistance to CDA. Because the zones of 
partial inhibition remained consistent throughout the study, it can be concluded that CDA 
treatment over 21 days did not result in resistance formation or preferential selection of 
strains with low sensitivity to CDA.   
Another objective of this study was to evaluate the changes in oral bacteria 
throughout a 21-day dosing with the 2.5% CDA-EVA mouthguard. Accordingly, subjects 
had a statistically significant decrease in the recoverable CFU from baseline to day 35 for 
both aerobic and anaerobic species. These results indicate that the level of CDA delivered to 
the sites of plaque sampling may have been sufficient to suppress the overall oral flora in the 
absence of any professional mechanical treatment. Alternatively, decreased bacterial levels 
may have been influenced by the Hawthorne effect. Maximum CDA levels measured in the 
saliva of each subject ranged from 1.7µg/ml to 13.8µg/ml (mean Cmax = 5.69 ±4.37 µg/ml)42 
throughout the course of the study and were greater than the MIC of S. mutans (aerobic) 
(0.39 µg/ml), P. gingivalis A7436 (1.56 µg/ml), P. gingivalis HG405 (1.56ug/ml µg/ml) and 
F. nucleatum (0.78 µg/ml ) as determined in our preliminary studies.28 
In our population of patients with minimal clinical signs of periodontal disease, a 
plethora of putative periodontal pathogens were identified in multiple sites.  This is 
consistent with Socransky and coworkers who reported that even in healthy sites with 3-5mm 
pocket depths, periodontal pathogens (e.g., P. gingivalis and P. intermedia) could be 
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recovered61. In the majority of healthy sites, the levels of these bacteria were typically less 
than 105. This finding is consistent with those of the present report where samples containing 
red and orange38 complex bacteria were detected at levels less than 105 in all but three sites. 
At the site level, no consistent pattern of microbial change could be identified; however, 
pooled data for all subjects showed a decrease in the percentage of plaque samples colonized 
with P .gingivalis and P. intermedia, which have been associated with periodontal pathology 
and progressive attachment loss.62 The lack of consistent microbial change at the site level 
may be due to the small sample size of this investigation as well as the minimal baseline 
clinical disease present in these subjects. 
Three subjects had sites positive for Candida species at baseline. In two of these 
subjects, there were no Candida species by day 35, and in the third subject Candida species 
were detected in only one of the two originally infected sites on Day 35. CHX is well 
documented as an anti-fungal agent. Hiom and coworkers have shown that CHX diacetate 
can have lethal activity against Candida albicans and Candida glabrata2. Additionally, 
Ferretti and coworkers63 showed in a double blind clinical trial that CHX oral rinse can 
control oral candidiasis in bone marrow transplantation patients. The trend for a reduction in 
Candida species following treatment with the CDA-EVA mouthguard may be important as 
we initiate the phase II trial in HIV-infected subjects who particularly susceptible to 
opportunistic infections with Candida species.64 
Conclusions 
The data suggest that the use of the 2.5% CDA-EVA drug delivery system is safe for use in 
medically healthy gingivitis subjects without the development of microbial resistance to 
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CDA or selection of putative/opportunistic pathogens. Additionally, the overall level of both 
aerobic and anaerobic microorganisms may be reduced with the use of the CDA-EVA 
mouthguard. While interpretation of the results of this small, unblinded clinical trial is 
limited, testing in HIV subjects with periodontal disease may proceed. 
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Table 1. 
Mean ±SD Baseline Clinical Parameters (N=6 subjects) 
 
 PD CAL %BOP PI GI 
      
Subject 1 2.39 1.90 42.9 0.23 0.69 
Subject 2 2.37 2.26 30.9 0.40 0.52 
Subject 3 2.49 2.24 52.0 0.46 1.02 
Subject 4 2.47 5.53 48.2 0.35 0.75 
Subject 5 2.53 2.06 57.7 0.66 1.49 
Subject 6 2.49 2.11 58.9 0.63 1.52 
All Subjects  2.46±0.06 2.19±0.22 48.45±10.49 0.45±0.17 1.00±0.42 
 
 
Table 2. 
Mean ± SD for Clinical Parameters at Baseline and Day 21 (N=6 subjects) 
 
Parameter Baseline Day 21 p* 
    
Mean PD (mm) 2.46±0.06 2.26±0.08 0.001 
Mean CAL (mm) 2.19±0.22 1.98±0.23 0.14 
Mean GI 1.00±0.42 0.54±0.18 0.03 
Mean PI 0.45±0.17 0.38±0.17 0.46 
Mean BOP (%) 48.45±10.49 30.76±9.22 0.002 
Mean CSSI 0.06±0.06 0.04±0.03 0.46 
Mean DI 0.07±0.04 0.05±0.05 0.47 
*Student t test 
 
 
 
Table 3. 
Mean ± SE for Clinical Parameters for the Maxillary Arch 
Adjusting for Mandibular Arch 
 
Parameter Baseline Day 21 p* 
    
Mean PD (mm) 2.38 (0.04) 2.21 (0.04) 0.04 
Mean CAL (mm) 1.99 (0.09) 1.90 (0.09) 0.54 
Mean GI 0.74 (0.11) 0.75 (0.11) 0.96 
Mean PI 0.42 (0.07) 0.34 (0.07) 0.42 
% BOP 44.6 (5.40) 34.4 (5.40) 0.26 
Mean CSSI (x100) 0.34 (0.50) 0.83 (0.50) 0.51 
Mean DI  0.09 (0.02) 0.06 (0.02) 0.41 
*ANCOVA 
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Table 4. 
Selective and non-selective media utilized for flora 
identification in sub-gingival plaque samples 
 
Aerobic Anaerobic 
BEA CBA 
Chocolate CVE 
MacConkey’s BBE 
Mycobiotic LKV 
Mannitol salt TSBV 
Saboraud’s Dextrose TSA-NAM 
Sheep blood agar Mitis-salivarius-
bacitracin 
 Campylobacter- 
Wolinella 
 
Lactobacillus 
selective 
 Mitis-salivarius 
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Figure 2. Concentration of CDA in saliva from Baseline to 24 hours for each 
subject (N=6) 
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Figure 3. Mean (SD) concentration of CDA in saliva from 
baseline to 24 hours  
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Figure 4. CDA concentration (µg/ml) in saliva day 1, 2, 3, 7, 14 and 21 prior to 
dosing and two hours post-dosing. (*p<0.05) 
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Figure 5. Mean (SD) Zones of Total and Partial Zones of Inhibition 
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Figure 6. Mean (SD) Total Recoverable Colony Forming Units (*p<0.05)  
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Figure 7. Percent of sites colonized with various bacteria 
on Day 0, Day 7 and Day 35 
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Figure 8. Number of sites colonized with Candida species 
on Day 0, Day 7 and Day 35 
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